Addex Therapeutics Ltd (ADXN) stock forecast & analysis
4.65
NasdaqCM · USDDelayed by 15 minutes
Down: -0.64, -12.1%
1 analysis
Latest analysis: · verdict locked
- Open
- 4.75
- Previous close
- 5.29
- Day range
- 4.50 – 4.77
- 52-week range
- 2.56 – 10.43
- Volume (shares)
- 225.39K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.75M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 2.07
- Market cap
- 8.15M
Market Scanner’s AI analysis of Addex Therapeutics Ltd (ADXN), updated November 2026: Neurosterix financing and clinical progress, alongside ADXN's share capital increase, contrasted with significant revenue decline and profitability concerns.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Addex Therapeutics Ltd (ADXN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Neurosterix financing and clinical progress, alongside ADXN's share capital increase, contrasted with significant revenue decline and profitability concerns.
Recent analyses for ADXN covered significant positive developments for its spin-out, Neurosterix, including a $105 million Series B financing and completion of Phase 1 clinical studies for its schizophrenia treatment. Addex Therapeutics also increased its issued share capital. However, the analyses also noted a substantial year-over-year quarterly revenue decline of 72.7% and negative TTM gross profit, alongside a high RSI indicating the asset is overbought.
ADXN news & sentiment
News reports highlighted significant positive developments for ADXN's spin-out, Neurosterix, including successful financing and clinical trial progress. Social media discussion focused on the stock's recent sharp price appreciation, with its high RSI indicating it is overbought.
ADXN technical picture
ADXN exhibited strong short-term price appreciation, with its current price above the 10-day EMA but below the 50-day and 200-day SMAs. Momentum readings, including RSI and MFI, indicated the asset was overbought, suggesting strong buying pressure.
Fundamentals
The company's recent quarterly revenue experienced a significant year-over-year decline, and its trailing twelve months gross profit was negative. Return on Equity was also substantially negative, indicating poor efficiency.
Factors discussed — upside
- Neurosterix closed a $105 million Series B financing round.
- Neurosterix completed Phase 1 clinical studies for its schizophrenia treatment.
- Addex Therapeutics increased its issued share capital.
- Strong short-term price appreciation with a 7-day change of +82.4% and 30-day change of +75.7%.
- Price is 66.1% above the 50-day SMA, indicating a strong recovery.
Factors discussed — risks
- Significant year-over-year quarterly revenue decline of 72.7%.
- TTM gross profit was negative (-272,177 CHF).
- Substantial net losses reported in recent years, with a net loss of -1,744,679 CHF in the latest reported quarter.
- Return on Equity (TTM) is -150.6%.
- RSI is at 80.75, indicating the asset is overbought.
- Biotechnology
- Clinical Development
- Financing Rounds
- Financial Performance
Summary updated .
ADXN technical indicators
Common technical indicators for ADXN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.20 | Price above |
| 10-day exponential moving average | 3.59 | Price above |
| Relative strength index (14-day) | 67.99 | Neutral |
| MACD line (12/26/9) | 0.2032 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 1.91 – 4.39 | Price above the upper band |
Analyses
Recent ADXN.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-13 ADXN.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Addex Therapeutics Ltd?
- The bull case for ADXN centers on significant positive developments for its spin-out, Neurosterix, which successfully closed a substantial Series B financing round and advanced its schizophrenia treatment into Phase 1 clinical studies. Addex Therapeutics also executed a share capital increase, and recent price action has shown strong short-term appreciation, with the stock price recovering significantly above its 50-day moving average.
- What are the risks for Addex Therapeutics Ltd?
- The bear case for ADXN highlights a considerable year-over-year quarterly revenue decline of 72.7% and negative trailing twelve months gross profit, alongside substantial net losses in recent reporting periods and a deeply negative Return on Equity. Furthermore, technical indicators suggest the asset is currently overbought, with the RSI well above the 70 threshold.
- Is Addex Therapeutics Ltd bullish or bearish?
- Recent AI analyses of Addex Therapeutics Ltd examined factors on both sides. Discussed upside: The bull case for ADXN centers on significant positive developments for its spin-out, Neurosterix, which successfully closed a substantial Series B financing round and advanced its schizophrenia treatment into Phase 1 clinical studies. Addex Therapeutics also executed a share capital increase, and recent price action has shown strong short-term appreciation, with the stock price recovering significantly above its 50-day moving average. Discussed risks: The bear case for ADXN highlights a considerable year-over-year quarterly revenue decline of 72.7% and negative trailing twelve months gross profit, alongside substantial net losses in recent reporting periods and a deeply negative Return on Equity. Furthermore, technical indicators suggest the asset is currently overbought, with the RSI well above the 70 threshold. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Addex Therapeutics Ltd?
- News reports highlighted significant positive developments for ADXN's spin-out, Neurosterix, including successful financing and clinical trial progress. Social media discussion focused on the stock's recent sharp price appreciation, with its high RSI indicating it is overbought.
- How does Market Scanner analyse Addex Therapeutics Ltd?
- Every analysis of Addex Therapeutics Ltd runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Addex Therapeutics Ltd?
The bull case for ADXN centers on significant positive developments for its spin-out, Neurosterix, which successfully closed a substantial Series B financing round and advanced its schizophrenia treatment into Phase 1 clinical studies. Addex Therapeutics also executed a share capital increase, and recent price action has shown strong short-term appreciation, with the stock price recovering significantly above its 50-day moving average.
What are the risks for Addex Therapeutics Ltd?
The bear case for ADXN highlights a considerable year-over-year quarterly revenue decline of 72.7% and negative trailing twelve months gross profit, alongside substantial net losses in recent reporting periods and a deeply negative Return on Equity. Furthermore, technical indicators suggest the asset is currently overbought, with the RSI well above the 70 threshold.
Is Addex Therapeutics Ltd bullish or bearish?
Recent AI analyses of Addex Therapeutics Ltd examined factors on both sides. Discussed upside: The bull case for ADXN centers on significant positive developments for its spin-out, Neurosterix, which successfully closed a substantial Series B financing round and advanced its schizophrenia treatment into Phase 1 clinical studies. Addex Therapeutics also executed a share capital increase, and recent price action has shown strong short-term appreciation, with the stock price recovering significantly above its 50-day moving average. Discussed risks: The bear case for ADXN highlights a considerable year-over-year quarterly revenue decline of 72.7% and negative trailing twelve months gross profit, alongside substantial net losses in recent reporting periods and a deeply negative Return on Equity. Furthermore, technical indicators suggest the asset is currently overbought, with the RSI well above the 70 threshold. These are descriptive observations, not a recommendation.
What is the latest sentiment on Addex Therapeutics Ltd?
News reports highlighted significant positive developments for ADXN's spin-out, Neurosterix, including successful financing and clinical trial progress. Social media discussion focused on the stock's recent sharp price appreciation, with its high RSI indicating it is overbought.
How does Market Scanner analyse Addex Therapeutics Ltd?
Every analysis of Addex Therapeutics Ltd runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh ADXN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.